Outcomes and complicatons of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmete-Guérin treatment failure

• Published in: Central European journal of urology 2020-07, Vol.73 (3), p.287-294
• Main Authors: Chiancone, Francesco, Fabiano, Marco, Fedelini, Maurizio, Meccariello, Clemente, Carrino, Maurizio, Fedelini, Paolo
• Format: Article
• Language: English
• Subjects: Bladder cancer; Cancer therapies; Chemotherapy; Immunotherapy; Multivariate analysis
• ISSN: 2080-4806; 2080-4873
• DOI: 10.5173/ceju.2020.0148

In the multivariate analysis, patients with tumor size >3 cm (p = .029), recurrence rate >l/year (p = .034), concomitant carcinoma in situ (CIS) during transurethral resection of bladder (TURB) (p = .039) and BCG-unresponsive status (p = .048) were associated with a worse response to chemohyperthermia. According to EAU (European Association of Urology) guidelines, 'BCG failure' was defined as any disease occurrence following BCG therapy and can be categorized into: 1) Muscle-invasive disease detected during follow-up; 2) BCG refractory [A: The inclusion criteria were as follows: 1) histological diagnosis of high-grade papillary Ta/Tl NMIBC alone or in combination with CIS [WHO 2014 grading system]; 2) the criteria of BCG-refractory, BCG-relapse, BCG-unresponsive or BCG intolerance disease were determined according to EAU guidelines criteria [2]; 3) adequate BCG treatment which is defined as having had BCG 6 weekly induction instillations followed by at least one 3 week maintenance course or a second induction course of 6 BCG instillations [4]. The study protocol was approved by the research ethics committee and all procedures performed in the study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.